newli
develop
sever
acut
respiratori
syndrom
sar
specif
enzymelink
immunosorb
assay
elisa
valid
confirm
cutoff
valu
evalu
diagnost
perform
clinic
sampl
parallel
immunochromatograph
test
also
evalu
total
clinic
serum
specimen
collect
sar
patient
use
studi
togeth
sampl
healthi
donor
use
immunofluoresc
test
gold
standard
elisa
immunochromatograph
test
abl
detect
immunoglobulin
g
antibodi
sar
lateconvalescentstag
sampl
day
onset
clinic
symptom
previous
establish
also
earlyacutephas
sampl
day
onset
elisa
use
optic
densiti
od
cutoff
valu
produc
best
sensit
maintain
high
specif
detect
sarsspecif
antibodi
respect
four
group
sampl
collect
patient
day
day
day
day
onset
clinic
symptom
similarli
immunochromatograph
test
detect
sarsspecif
antibodi
four
group
respect
overal
specif
elisa
rapid
test
respect
although
posit
correl
observ
elisa
od
valu
titer
moder
r
p
detect
rate
elisa
rapid
test
found
well
agreement
titer
given
number
true
posit
detectedtot
number
sampl
test
posit
percent
ppv
npv
calcul
use
result
healthi
donor
hong
kong
hd
hk
sar
patient
total
obtain
test
site
hong
kong
e
npv
number
true
neg
detectedtot
number
sampl
test
neg
percent
given
number
posit
samplesnumb
sampl
test
percent
b
given
number
neg
samplesnumb
sampl
test
percent
hd
hk
serum
sampl
healthi
donor
hong
kong
titer
determin
nonsar
diseas
control
c
given
number
true
posit
detectedtot
number
sampl
test
posit
percent
ppv
npv
calcul
use
result
healthi
donor
hong
kong
hd
hk
sar
patient
total
obtain
test
site
hong
kong
e
npv
number
true
neg
detectedtot
number
sampl
test
neg
percent
tabl
agreement
new
rapid
test
new
elisa
sera
sar
patient
healthi
control
result
rapid
test
elisa
result
agreement
posit
neg
posit
neg
kappa
statist
obtain
kappa
statist
repres
excel
agreement
repres
good
fair
agreement
repres
poor
agreement
newli
emerg
sever
acut
respiratori
syndrom
sar
seriou
respiratori
ill
global
signific
highli
contagi
natur
combin
high
mortal
rate
proven
disrupt
costli
increasingli
global
world
new
case
appear
reemerg
januari
urgenc
prompt
identif
isol
infect
patient
remain
although
identif
novel
coronaviru
sar
coronaviru
sarscov
etiolog
agent
sar
made
possibl
variou
test
develop
provid
tool
laboratori
diagnosi
remain
prioriti
suggest
world
health
organ
date
still
standard
test
diagnos
sar
regardless
whether
test
antigen
base
antibodi
base
http
wwwwhointcsrsarsconferencejun
regard
variou
immunofluoresc
test
essenti
use
gold
standard
serodiagnosi
sar
outbreak
although
protocol
found
well
correl
pcr
clinic
outcom
differ
laboratori
laboratori
technic
demand
addit
protocol
util
virusinfect
materi
thu
requir
laboratori
facil
current
regul
henc
altern
test
standard
approach
address
shortcom
much
need
howev
thorough
evalu
standard
panel
trial
use
larg
number
clinic
specimen
help
firmli
establish
use
new
test
studi
two
newli
develop
serolog
test
evalu
valid
larg
number
sampl
two
test
enzymelink
immunosorb
assay
elisa
immunochromatograph
test
base
recombin
protein
demonstr
excel
perform
test
convalescentphas
sampl
sar
patient
previou
studi
present
expans
includ
earlier
specimen
acutephas
patient
well
larg
number
relev
control
provid
realist
assess
perform
two
test
serolog
diagnosi
sar
clinic
set
serum
specimen
serum
specimen
collect
patient
present
suspect
clinic
sar
accord
definit
admit
one
three
acutecar
region
hospit
hong
kong
march
may
total
serum
sampl
patient
test
use
test
confirm
titer
meantim
serum
sampl
collect
local
healthi
donor
hong
kong
use
control
sampl
also
test
test
confirm
titer
addit
serum
sampl
healthi
donor
purchas
bioclin
partner
inc
franklin
mass
includ
studi
addit
healthi
control
diseas
control
serum
sampl
variou
previou
studi
genelab
diagnost
singapor
archiv
use
includ
sampl
patient
nonsarsrel
fever
confirm
dengu
fever
suffer
nonsarsrel
respiratori
ill
confirm
tuberculosi
test
test
prepar
carri
describ
yam
et
al
briefli
smear
sarscovinfect
vero
cell
prepar
fix
aceton
min
store
use
batch
smear
sarscovinfect
cell
hightit
verifi
use
positivecontrol
serum
sampl
use
patient
sampl
prepar
serial
twofold
dilut
start
ad
smear
incub
min
smear
wash
twice
phosphatebuff
salin
pb
incub
min
goat
antihuman
immunoglobulin
g
igg
label
fluorescein
isothiocyan
sampl
score
posit
fluoresc
intens
equal
higher
weakli
posit
control
includ
studi
elisa
elisa
produc
genelab
diagnost
pte
ltd
singapor
util
two
recombin
protein
gstn
previous
describ
assay
carri
strictli
follow
instruct
provid
briefli
quantiti
serum
specimen
l
trisbas
diluent
contain
bovin
serum
albumin
skim
milk
powder
ad
appropri
well
elisa
plate
incub
min
follow
six
wash
pbstween
horseradish
peroxidaseconjug
goat
antihuman
igg
dilut
ad
l
per
well
incub
min
plate
wash
six
time
pbstween
color
develop
carri
addit
l
enzym
substrat
tetramethylbenzidin
tmb
per
well
incub
dark
reaction
stop
ad
l
n
hcl
per
well
optic
densiti
od
measur
nm
refer
filter
rapid
immunochromatograph
test
membranebas
test
devic
also
produc
genelab
diagnost
pte
ltd
singapor
follow
procedur
previous
describ
devic
consist
chromatographi
strip
separ
absorb
pad
hous
cassett
describ
previous
two
sarsspecif
recombin
protein
gstn
deposit
separ
chromatographi
strip
accord
detail
descript
guan
et
al
test
sampl
contain
antibodi
sarscov
antibodi
would
bind
either
immobil
recombin
immunocomplex
form
could
detect
immobil
colloid
gold
label
antihuman
igg
latter
releas
reagentreleas
wash
buffer
assay
also
carri
strictli
follow
instruct
provid
manufactur
briefli
l
serum
sampl
ad
sampl
well
allow
migrat
later
cover
portion
membran
resultview
window
three
drop
reagentreleas
wash
buffer
ad
second
well
serum
sampl
wet
front
reach
blue
indic
line
view
window
separ
tab
pull
resist
felt
addit
drop
reagentreleas
wash
buffer
ad
sampl
well
result
typic
read
view
window
min
record
min
sampl
score
neg
control
line
appear
posit
control
line
either
test
line
seen
view
window
statist
analysi
delta
valu
defin
distanc
mean
od
cutoff
ratio
sampl
popul
cutoff
measur
standard
deviat
sd
calcul
valid
cutoff
valu
kappa
statist
use
measur
strength
agreement
result
new
rapid
test
new
elisa
kappa
statist
repres
excel
good
fair
poor
agreement
respect
evalu
valid
elisa
present
tabl
three
cutoff
valu
od
use
evalu
perform
elisa
cutoff
valu
set
od
elisa
produc
best
specif
low
overal
sensit
tabl
howev
improv
perform
obtain
cutoff
valu
adjust
lower
od
elisa
de
tect
almost
sarsassoci
sampl
overal
od
cutoff
valu
od
set
tabl
improv
delta
valu
posit
result
also
obtain
supplementari
test
sampl
healthi
control
test
mean
od
obtain
od
found
equival
mean
od
sd
wherea
od
found
equival
mean
od
sd
two
cutoff
valu
produc
similarli
high
specif
versu
versu
versu
supplement
healthycontrol
group
nonsar
control
respiratori
ill
nonsar
control
fever
respect
tabl
cutoff
set
od
elisa
detect
igg
antibodi
sarscov
lateconvalescentstag
sampl
high
sensit
also
acutephas
specimen
detect
igg
antibodi
sarscov
sampl
collect
sar
patient
day
day
day
onset
clinic
symptom
respect
specif
obtain
cutoff
od
remain
high
healthycontrol
group
test
test
site
tabl
test
thu
provid
overal
posit
predict
valu
ppv
overal
neg
predict
valu
npv
moder
posit
correl
also
observ
elisa
od
valu
titer
r
p
fig
howev
correl
held
firm
elisa
detect
antibodi
sarscov
progress
patient
sampl
titer
increas
fig
evalu
rapid
immunochromatograph
test
set
clinic
specimen
test
rapid
immunochromatograph
test
perform
similar
elisa
obtain
overal
rate
detect
sarsassoci
specimen
rapid
test
specif
tabl
detect
rate
respect
four
group
sampl
collect
sar
patient
day
day
day
day
onset
clinic
symptom
tabl
test
util
two
recombin
protein
separ
repres
two
result
band
perform
two
protein
also
analyz
gstn
protein
alon
detect
antibodi
sarscov
sampl
found
posit
two
protein
combin
tabl
furthermor
gstn
protein
present
less
crossreact
react
specimen
healthycontrol
group
contrast
detect
overal
sarsassoci
sampl
contribut
nonspecif
reactiv
sampl
healthi
control
interestingli
three
sampl
detect
gstn
protein
collect
patient
earlier
stage
day
onset
clinic
symptom
tabl
test
therefor
shown
ppv
npv
respect
popul
test
tabl
supplementari
test
rapid
test
evalu
diseas
control
group
consist
nonsar
patient
suffer
respiratori
ill
fever
found
crossreact
sampl
test
respect
group
tabl
result
compar
rapid
test
elisa
gave
excel
overal
agreement
kappa
statist
tabl
addit
rapid
test
also
found
perform
well
concord
titer
detect
progress
patient
sampl
titer
increas
fig
sar
new
human
thu
mani
aspect
diseas
etiolog
agent
sarscov
yet
fulli
understood
exampl
appar
contradictori
phenomenon
high
infect
rate
health
care
worker
low
infect
rate
famili
member
yet
fulli
explain
appear
viral
load
low
earli
infect
week
infect
situat
render
pcr
techniqu
rel
insensit
earli
stage
infect
serolog
approach
test
demonstr
welcom
complementari
tool
combat
sar
fact
test
practic
use
gold
standard
serodiagnosi
sar
hospit
outbreak
despit
limit
nevertheless
new
approach
need
test
use
refer
evalu
previou
studi
newli
develop
elisa
rapid
immunochromatograph
test
demonstr
excel
perform
ppv
npv
higher
suggest
great
potenti
least
exclus
sar
studi
tool
epidemiologist
howev
studi
limit
convalescentphas
sampl
sar
patient
use
new
test
clinic
diagnosi
sar
thu
remain
fulli
verifi
present
studi
two
new
test
evalu
perform
patient
sampl
sampl
healthi
control
furthermor
studi
includ
valid
cutoff
valu
use
addit
sampl
healthi
donor
sampl
diseas
control
studi
thu
allow
us
finetun
cutoff
valu
elisa
data
show
adjust
cutoff
od
produc
best
sensit
elisa
without
compromis
specif
much
tabl
awar
risk
falseposit
result
sarscov
test
high
postoutbreak
period
thu
recommend
test
algorithm
minim
falseposit
result
lowrisk
area
enhanc
surveil
higherrisk
area
http
wwwwhointcsrsarsguidelin
ensarslabmeetingpdf
view
recommend
may
appropri
set
higher
cutoff
valu
ppv
elisa
use
lowrisk
area
order
minim
possibl
falseposit
result
similarli
lower
cutoff
valu
increas
sensit
higher
npv
may
desir
appropri
elisa
use
higherrisk
area
case
western
blot
test
verifi
confirm
result
sampl
repeatedli
test
posit
elisa
especi
case
borderlin
posit
help
resolv
falseposit
thu
studi
warrant
detect
rate
sampl
obtain
day
onset
clinic
symptom
tabl
present
data
confirm
previou
find
elisa
excel
detect
antibodi
sar
convalescentphas
sampl
although
elisa
yield
overal
sensit
shortcom
attribut
perform
sampl
obtain
earlier
day
onset
clinic
symptom
tabl
new
test
detect
group
tabl
howev
noteworthi
detect
rate
signific
improv
captur
elisa
report
recent
detect
igg
antibodi
equival
group
perhap
also
noteworthi
igg
antibodi
sar
cov
believ
reach
peak
valu
around
day
onset
obviou
symptom
center
diseas
control
prevent
recommend
includ
part
case
definit
exclus
sar
absenc
antibodi
viru
convalescentphas
serum
sampl
obtain
day
onset
ill
similarli
rapid
test
found
overal
detect
rate
compar
elisa
shortcom
due
result
earli
group
tabl
although
rapid
test
util
two
recombin
protein
gstn
latter
appear
contribut
littl
sensit
kit
nonspecif
reactiv
healthi
control
detect
patient
sampl
crossreact
healthycontrol
sampl
tabl
discuss
previous
biolog
function
yet
unravel
util
protein
diagnost
marker
thu
yet
fulli
understood
present
studi
appear
suggest
limit
protein
howev
interest
three
sampl
detect
gstn
collect
patient
earlier
group
day
onset
clinic
symptom
posit
correl
observ
elisa
od
titer
moder
correl
coeffici
r
p
fig
find
suggest
elisa
od
titer
moder
associ
differ
two
approach
could
due
fact
new
test
util
recombin
protein
rather
virusinfect
cell
use
test
howev
noteworthi
overal
perform
elisa
rapid
test
well
concord
titer
new
test
detect
progress
patient
sampl
titer
increas
fig
find
thu
suggest
shortcom
new
test
mostli
limit
sampl
titer
lower
fig
nevertheless
two
new
test
similar
overal
sensit
specif
rel
test
use
gold
standard
tabl
two
test
compar
gave
overal
agreement
kappa
statist
tabl
confirm
previou
find
suggest
although
immunochromatograph
test
simpl
rapid
test
need
special
train
use
perform
fulli
compat
elisa
immunochromatograph
test
valuabl
addit
current
option
combat
sar
especi
area
laboratori
facil
avail
